“There’s an incredible opportunity to think about how we bring immunotherapy into earlier interventions and really intercept cancer so that we don’t present with stage 3, stage 4 disease later,”
STAT Summit stage
“Novartis now expects to speak with the FDA about a potential accelerated approval of pelabresib before the end of the year, CEO Vas Narasimhan told investors on a call Tuesday.”
“The industry has gotten more consolidated. Prices are higher than ever. Access is worse than ever.”
“The rising costs are unsustainable for individuals, for businesses, and for the country. What kind of intervention is a different question.”